Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 9/20 | 0.63 |
| ▸ | PFKFB4 | Q16877 | 9/20 | 0.63 |
| ▸ | CMA1 | P23946 | 4/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3884692 | 0.86 | PFKFB3 (0.71) | PFKFB3PFKFB4CMA1F10NPSR1 | |
| SCHEMBL3886516 | 0.84 | PFKFB3 (0.54) | PFKFB3PFKFB4CMA1 | |
| SCHEMBL3555875 | 0.80 | PFKFB3 (0.83) | PFKFB3PFKFB4CMA1NPSR1L3MBTL1 | |
| SCHEMBL3879417 | 0.79 | PFKFB3 (0.61) | PFKFB3PFKFB4CMA1MRGPRX4F10 | |
| SCHEMBL3553777 | 0.78 | PFKFB3 (0.77) | PFKFB3PFKFB4CMA1NPSR1L3MBTL1 | |
| SCHEMBL788108 | 0.77 | PFKFB4 (1.00) | PFKFB3PFKFB4CMA1NPSR1L3MBTL1 | |
| Propane SCHEMBL28642185 | 0.77 | PFKFB4 (0.94) | PFKFB3PFKFB4CMA1NPSR1L3MBTL1 | |
| SCHEMBL3876651 | 0.77 | PFKFB4 (0.72) | PFKFB3PFKFB4CMA1F10NPSR1 | |
| SCHEMBL3556078 | 0.76 | PFKFB3 (0.67) | PFKFB3PFKFB4CMA1HTR6 | |
| SCHEMBL3883349 | 0.76 | MRGPRX4 (0.52) | MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814846-B1 | 11BETA-HSD1 INHIBITORS | EVOTEC AG (DE) | 2009-04-08 | — | — | EP | disclosed |
| US-20090069323-A1 | 11beta-hsdi inhibitors | EVOTEC AG (DE) | 2009-03-12 | — | — | US | disclosed |
| EP-1814846-A1 | 11BETA-HSD1 INHIBITORS | Evotec AG (DE) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006048330-A1 | 11ΒΕΤΑ-HSD1 INHIBITORS | EVOTEC AG (DE) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069323-A1 | 11beta-hsdi inhibitors | HSD3B1, HSD3B2, HSD11B1 | PFKFB3 1134/4885PFKFB4 1312/4885CMA1 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.